BioNTech SE Statistics
BioNTech SE (22UA) Stock Statistics & Valuation Metrics
Total Valuation
BioNTech SE has a market cap or net worth of CHF 17.85B. The enterprise value is CHF 9.59B.
- Market Cap
- CHF 17.85B
- Enterprise Value
- CHF 9.59B
Share Statistics
BioNTech SE has 251,204,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 251,204,360
- Owned by Insiders
- 15.80%
- Owned by Institutions
- 9.90%
Financial Efficiency
BioNTech SE’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -3.14%.
- Return on Equity (ROE)
- -0.06
- Return on Assets (ROA)
- -0.05
- Return on Invested Capital (ROIC)
- -3.14%
- Return on Capital Employed (ROCE)
- -0.03
- Revenue Per Employee
- 353.10K
- Profits Per Employee
- -139.78K
- Employee Count
- 7,807
- Asset Turnover
- 0.13
- Inventory Turnover
- 5.57
Valuation Ratios
The current PE Ratio of BioNTech SE is -13.35. BioNTech SE’s PEG ratio is 0.14.
- PE Ratio
- -13.35
- PS Ratio
- 8.08
- PB Ratio
- 1.11
- Price to FCF
- -41.56
- Price to Operating Cash Flow
- -79.77
- PEG Ratio
- 0.14
Income Statement
In the last 12 months, BioNTech SE had revenue of 2.76B and earned -1.09B in profits. Earnings per share was -4.51.
- Revenue
- 2.76B
- Gross Profit
- 2.14B
- Operating Income
- -623.87M
- Pretax Income
- -1.01B
- Net Income
- -1.09B
- EBITDA
- -628.00M
- Earnings Per Share (EPS)
- -4.51
Cash Flow
In the last 12 months, operating cash flow was -247.56M and capital expenditures -208.64M, giving a free cash flow of -456.19M billion.
- Operating Cash Flow
- -247.56M
- Free Cash Flow
- -456.19M
- Free Cash Flow per Share
- -1.88
Dividends & Yields
BioNTech SE pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -2.42%
- Earnings Yield
- -7.62%
Stock Price Statistics
- Beta
- 0.60
- 52-Week Price Change
- 1.14%
- 50-Day Moving Average
- 78.28
- 200-Day Moving Average
- 77.09
- Relative Strength Index (RSI)
- 42.23
- Average Volume (3m)
- 91
Important Dates
BioNTech SE upcoming earnings date is Mar 02, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
BioNTech SE as a current ratio of 7.54, with Debt / Equity ratio of 1.39%
- Current Ratio
- 7.54
- Quick Ratio
- 7.49
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 11.79
- Interest Coverage Ratio
- -45.74
Taxes
In the past 12 months, BioNTech SE has paid 81.93M in taxes.
- Income Tax
- 81.93M
- Effective Tax Rate
- -0.08
Enterprise Valuation
BioNTech SE EV to EBITDA ratio is -22.28, with an EV/FCF ratio of -20.32.
- EV to Sales
- 3.95
- EV to EBITDA
- -22.28
- EV to Free Cash Flow
- -20.32
- EV to Operating Cash Flow
- -38.79
Balance Sheet
BioNTech SE has CHF 10.20B in cash and marketable securities with CHF 359.80M in debt, giving a net cash position of CHF 9.84B billion.
- Cash & Marketable Securities
- CHF 10.20B
- Total Debt
- CHF 359.80M
- Net Cash
- CHF 9.84B
- Net Cash Per Share
- CHF 39.18
- Tangible Book Value Per Share
- CHF 64.80
Margins
Gross margin is 67.86%, with operating margin of -63.12%, and net profit margin of -61.53%.
- Gross Margin
- 67.86%
- Operating Margin
- -63.12%
- Pretax Margin
- -59.89%
- Net Profit Margin
- -61.53%
- EBITDA Margin
- -17.72%
- EBIT Margin
- -54.50%
Analyst Forecast
The average price target for BioNTech SE is CHF 100.05, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- CHF 100.05
- Price Target Upside
- 39.62% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 16
- Revenue Growth Forecast
- -23.63%
- EPS Growth Forecast
- -140.38%
Scores
- Smart Score
- 9
- AI Score
- ―
